Immunome IMNM Increase Decrease In Accrued Expenses And Other Current Liabilities
Increase Decrease In Accrued Expenses And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept imnm:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's increase decrease in accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's increase decrease in accrued expenses and other current liabilities?
- Immunome (IMNM) reported increase decrease in accrued expenses and other current liabilities of -$9.75M in Q1 2026.
- How has Immunome's increase decrease in accrued expenses and other current liabilities changed year-over-year?
- Immunome's increase decrease in accrued expenses and other current liabilities decreased by 14.4% year-over-year, from -$8.52M to -$9.75M.
- What is the long-term trend for Immunome's increase decrease in accrued expenses and other current liabilities?
- Over 2 years (2021 to 2024), Immunome's increase decrease in accrued expenses and other current liabilities has grown at a 60.2% compound annual growth rate (CAGR), from $5.28M to $13.55M.
- What does increase decrease in accrued expenses and other current liabilities mean?
- This reflects the net change in liabilities for expenses that have been incurred but not yet paid, such as compensation, professional fees, or operational costs. An increase indicates a deferral of cash outflows, while a decrease represents the settlement of these obligations. It serves as a key indicator of short-term working capital management and liquidity timing.